NCT06098651 is a Phase 1 clinical trial of DCR-STAT3 in Solid Tumor, Adult, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.

Who is sponsoring NCT06098651?

NCT06098651 is sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.

What drugs are being tested in NCT06098651?

Interventions in NCT06098651: DCR-STAT3.

What condition does NCT06098651 study?

NCT06098651 studies Solid Tumor, Adult, Refractory Tumor.

Is NCT06098651 still recruiting?

NCT06098651 is currently completed. Last updated 29 September 2025.

Last reviewed 2025-09-29 · How we verify

NCT06098651

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of DCR-STAT3 in Adults With Solid Tumors

Completed Phase 1 Last updated 29 September 2025

What this trial tests

Phase 1 trial testing DCR-STAT3 in Solid Tumor, Adult in 26 participants. Completed in 17 September 2025.

Timeline

14 August 2023

Primary endpoint
17 September 2025

17 September 2025

Quick facts

Lead sponsor	Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	14 August 2023
Primary completion	17 September 2025
Estimated completion	17 September 2025
Sites	2 locations across United States

Drugs / interventions tested

DCR-STAT3 — full drug profile →

Conditions studied

Solid Tumor, Adult — all drugs for Solid Tumor, Adult →
Refractory Tumor — all drugs for Refractory Tumor →

Sponsor

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company — full company profile →

Who can join

18 and older, any sex, with Solid Tumor, Adult or Refractory Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a sequential, ascending-dose, multicenter study conducted in patients with refractory solid tumors designed to evaluate the safety, tolerability, and pharmacokinetics of DCR-STAT3.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical landscape of macrophage-reprogramming cancer immunotherapies.
Rannikko JH, Hollmén M. · · 2024 · cited 70× · PMID 38831013 · DOI 10.1038/s41416-024-02715-6
RNAi mediated silencing of STAT3/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors.
Ganesh S, Kim MJ, Lee J, Feng X, et al · · 2024 · cited 19× · PMID 38549376 · DOI 10.1016/j.ymthe.2024.03.035
Metabolic reprogramming in cancer and senescence.
Zhang Y, Tang J, Jiang C, Yi H, et al · · 2025 · cited 13× · PMID 40046406 · DOI 10.1002/mco2.70055
siRNA tackles cancer: Immune checkpoint inhibitors and siRNA combinations.
Coles AH. · · 2025 · cited 3× · PMID 39867573 · DOI 10.1016/j.omtn.2024.102429
Macrophage Zc3h12c Limits Tissue Inflammation and Injury via Alternative Splicing of Pre-mRNA.
Li C, Marschner JA, Kusunoki Y, Zhang N, et al · · 2025 · cited 2× · PMID 40834429 · DOI 10.1002/advs.202506707
Clinical development prospects of siRNA drugs for tumor therapy: analysis of clinical trial registration data from 2004 to 2024.
Wang CE, Zhen D, Yang L, Li G. · · 2025 · cited 1× · PMID 41041638 · DOI 10.3389/fphar.2025.1637958

Verify or expand the search:

Other recruiting trials for Solid Tumor, Adult

Currently open trials in the same condition.

NCT07139990 — Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) · Phase 1 · recruiting
NCT06398418 — R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients · Phase 1 · recruiting
NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
NCT07137195 — Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) · NA · active not recruiting
NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting

Other Dicerna Pharmaceuticals, Inc., a Novo Nordisk company trials

Trials by the same sponsor.

NCT06504368 — Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors · Phase 1 · recruiting
NCT05845398 — Phase 1b Study of DCR-AUD in Healthy Volunteers · Phase 1 · completed
NCT05001269 — Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function · Phase 2 · completed
NCT05021640 — Study of DCR-AUD in Healthy Volunteers · Phase 1 · completed
NCT04542590 — Natural History of Patients With PH3 and a History of Stone Events · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06098651 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Last refreshed: 29 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06098651.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing